STRATA Skin Sciences Future Growth
Future criteria checks 1/6
STRATA Skin Sciences is forecast to grow earnings and revenue by 62.1% and 9.6% per annum respectively while EPS is expected to grow by 64.2% per annum.
Key information
62.1%
Earnings growth rate
64.2%
EPS growth rate
Medical Equipment earnings growth | 17.0% |
Revenue growth rate | 9.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%
Aug 18Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?
Aug 07STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business
Jun 07Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Nov 03We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Jul 04STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
Apr 18Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Jan 14STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M
Aug 10Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment
Jul 25What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 09Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years
Nov 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 40 | -1 | N/A | 7 | 1 |
12/31/2025 | 37 | -4 | N/A | 4 | 1 |
12/31/2024 | 33 | -7 | N/A | 0 | 1 |
9/30/2024 | 33 | -9 | -2 | 1 | N/A |
6/30/2024 | 33 | -8 | -3 | -1 | N/A |
3/31/2024 | 33 | -11 | -4 | -1 | N/A |
12/31/2023 | 33 | -11 | -6 | -1 | N/A |
9/30/2023 | 35 | -7 | -6 | -2 | N/A |
6/30/2023 | 36 | -7 | -6 | 0 | N/A |
3/31/2023 | 37 | -6 | -6 | -1 | N/A |
12/31/2022 | 36 | -6 | -5 | -1 | N/A |
9/30/2022 | 35 | -6 | -4 | 0 | N/A |
6/30/2022 | 33 | -6 | -3 | 1 | N/A |
3/31/2022 | 31 | -3 | -3 | 1 | N/A |
12/31/2021 | 30 | -3 | -2 | 2 | N/A |
9/30/2021 | 28 | -2 | -2 | 1 | N/A |
6/30/2021 | 26 | -3 | -2 | 1 | N/A |
3/31/2021 | 22 | -6 | -1 | 2 | N/A |
12/31/2020 | 23 | -4 | 0 | 2 | N/A |
9/30/2020 | 25 | -4 | N/A | 3 | N/A |
6/30/2020 | 27 | -4 | 0 | 3 | N/A |
3/31/2020 | 31 | -3 | 0 | 2 | N/A |
12/31/2019 | 32 | -4 | -1 | 2 | N/A |
9/30/2019 | 31 | -3 | 0 | 2 | N/A |
6/30/2019 | 31 | -3 | 2 | 3 | N/A |
3/31/2019 | 31 | -3 | 1 | 3 | N/A |
12/31/2018 | 30 | -4 | 1 | 3 | N/A |
9/30/2018 | 31 | -9 | 2 | 4 | N/A |
6/30/2018 | 30 | -22 | N/A | 2 | N/A |
3/31/2018 | 31 | -21 | N/A | 3 | N/A |
12/31/2017 | 32 | -22 | N/A | 4 | N/A |
9/30/2017 | 30 | -18 | N/A | 4 | N/A |
6/30/2017 | 31 | -6 | N/A | 4 | N/A |
3/31/2017 | 30 | -4 | N/A | 3 | N/A |
12/31/2016 | 31 | -3 | N/A | 0 | N/A |
9/30/2016 | 33 | -3 | N/A | -1 | N/A |
6/30/2016 | 33 | -14 | N/A | -3 | N/A |
3/31/2016 | 26 | -22 | N/A | -5 | N/A |
12/31/2015 | 18 | -28 | N/A | -7 | N/A |
9/30/2015 | 9 | -34 | N/A | -10 | N/A |
6/30/2015 | 1 | -24 | N/A | -12 | N/A |
3/31/2015 | 1 | -15 | N/A | -14 | N/A |
12/31/2014 | 1 | -16 | N/A | -18 | N/A |
9/30/2014 | 1 | -14 | N/A | -19 | N/A |
6/30/2014 | 1 | -19 | N/A | -20 | N/A |
3/31/2014 | 0 | -27 | N/A | -20 | N/A |
12/31/2013 | 1 | -26 | N/A | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SSKN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SSKN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SSKN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SSKN's revenue (9.6% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: SSKN's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 16:04 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
STRATA Skin Sciences, Inc. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gregory Chodaczek | Boenning & Scattergood, Inc. |
Jose Teodorico De Jesus Haresco | Brean Capital |
null null | CG Capital |